Corporate Website
Africa
Argentina
Asia
Australia
Belgium
Brazil
Bulgaria
Canada (EN)
Chile
China
Colombia
Denmark
Egypt
France
Germany
Greece
Hungary
Indonesia
Italia
India
Japan
Korea
Malaysia
Mexico
Middle East
Netherlands
Peru
Philippines
Poland
Portugal
Romania
Russia
South Africa
Spain
Sweden
Thailand
Tunisia
Turkey
Ukraine
United Kingdom
USA
Vietnam
You are leaving the country website to access another site in the group.
Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.
Corporate Website
Africa
Argentina
Asia
Australia
Belgium
Brazil
Bulgaria
Canada (EN)
Chile
China
Colombia
Denmark
Egypt
France
Germany
Greece
Hungary
Indonesia
Italia
India
Japan
Korea
Malaysia
Mexico
Middle East
Netherlands
Peru
Philippines
Poland
Portugal
Romania
Russia
South Africa
Spain
Sweden
Thailand
Tunisia
Turkey
Ukraine
United Kingdom
USA
Vietnam
You are leaving the country website to access another site in the group.
Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.
Reg. SAGARPA Q-7378-029
Inducción del celo, sincronización del estro, control del puerperio, cuerpo lúteo persistente o quístico, inducción del aborto/parto, tratamiento infecciones uterinas (piometras, endometritis), tratamiento y prevención de las retenciones placentarias.
Cada l00ml. contienen: Alfaprostol 200 mg. Vehículo c.b.p. 100 ml.
Intramuscular.
Frascos de vidrio de 20 ml.
Volver arriba
